Groupama Asset Managment Sells 2,849 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Groupama Asset Managment cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,521,385 shares of the biopharmaceutical company's stock after selling 2,849 shares during the period. Groupama Asset Managment owned about 1.18% of Alnylam Pharmaceuticals worth $418,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ALNY. Eventide Asset Management LLC increased its stake in Alnylam Pharmaceuticals by 157.9% in the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company's stock valued at $61,698,000 after buying an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock valued at $37,684,000 after acquiring an additional 135,829 shares during the last quarter. AQR Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 92.5% during the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company's stock worth $65,862,000 after acquiring an additional 130,482 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $29,111,000. Finally, Avoro Capital Advisors LLC boosted its position in Alnylam Pharmaceuticals by 33.3% during the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company's stock valued at $97,200,000 after purchasing an additional 100,000 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. The Goldman Sachs Group raised Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the company from $198.00 to $370.00 in a report on Friday, August 16th. HC Wainwright reiterated a "buy" rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Piper Sandler reiterated an "overweight" rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $298.09.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,469 shares of the company's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company's stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares in the company, valued at $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,370 shares of company stock valued at $2,100,703 over the last ninety days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ:ALNY traded down $1.98 during mid-day trading on Tuesday, hitting $253.91. The company had a trading volume of 463,274 shares, compared to its average volume of 864,279. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The company has a market capitalization of $32.75 billion, a PE ratio of -96.91 and a beta of 0.32. The firm has a fifty day moving average price of $268.29 and a 200 day moving average price of $247.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The firm's revenue for the quarter was down 33.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.15 earnings per share. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.